Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus.
about
Effects of aging and type 2 diabetes on resting and post occlusive hyperemia of the forearm; the impact of rosiglitazoneInsulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetesNeurovascular function and sudorimetry in health and disease.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.Low fingertip temperature rebound measured by digital thermal monitoring strongly correlates with the presence and extent of coronary artery disease diagnosed by 64-slice multi-detector computed tomography.Mechanisms of coronary microvascular adaptation to obesity.Review of approved pioglitazone combinations for type 2 diabetes.Microcirculation on a large scale: techniques, tactics and relevance of studying the microcirculation in larger population samples.Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.Protective Actions of PPAR-gamma Activation in Renal Endothelium.Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes.Diabetes, cardiovascular disease and the microcirculation.
P2860
Q24792848-A361C79A-740F-4626-91D0-02DB4C56F9F1Q33880303-DE7A204B-DB66-47B7-8794-38CD1B10B7CFQ34509903-85DC4CAC-68B3-42A9-B9BC-C98587FB2B15Q34726851-046D2B42-AB05-43BA-8B03-F14B71815E23Q37107490-8C9500AE-87F8-4BF1-8CEE-4C346D97BAC6Q37142138-B50976B2-8066-4B62-91FC-15103AF34264Q37311870-361573B1-32D9-4D5C-8467-AE0BC1B792B8Q37522921-24B5EF84-34F5-45B7-9F45-4A0C86377343Q37884618-31640F63-66B3-43F0-B7F9-5053D22CF84CQ37942591-FE231E34-1566-4306-89BB-8CD5FA9A27F1Q41434069-6C331B06-7F7A-4F25-9F40-2008065F3906Q42008239-BA101F22-9B9D-4672-9FE9-3AF436FBE84EQ42648120-EA6749D6-F805-45F1-8F1B-8C73B6F5F470Q54986438-079AD68A-A47C-4443-BB9E-713531E72A1F
P2860
Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@ast
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@en
type
label
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@ast
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@en
prefLabel
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@ast
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@en
P2093
P1476
Rosiglitazone treatment increa ...... with type 2 diabetes mellitus.
@en
P2093
Aaron I Vinik
Kevin B Stansberry
Patricia M Barlow
P304
P356
10.1016/S1056-8727(03)00006-0
P577
2003-09-01T00:00:00Z